A5055910619- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- Gastrointestinal Tumor Research and Treatment
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Soft tissue tumor case studies
- Genetic factors in colorectal cancer
- Cytokine Signaling Pathways and Interactions
- Autoimmune and Inflammatory Disorders
- Problem and Project Based Learning
- Inflammatory Bowel Disease
- Colorectal Cancer Screening and Detection
- Oral and Maxillofacial Pathology
- Sarcoma Diagnosis and Treatment
- Liver Diseases and Immunity
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Helicobacter pylori-related gastroenterology studies
- Simulation-Based Education in Healthcare
- Occupational and environmental lung diseases
- Microscopic Colitis
- Cancer Genomics and Diagnostics
- Pleural and Pulmonary Diseases
- Cancer, Stress, Anesthesia, and Immune Response
- Biomedical and Engineering Education
McGill University Health Centre
2021-2025
University of Chicago
2023-2024
GTx (United States)
2023
McGill University
2022-2023
Montreal General Hospital
2023
Abstract Liver fibrosis is a global health problem. IL-17A has proven profibrogenic properties in liver disease making it an interesting therapeutic target. regulated by RORγt and produced Th17 CD4+ γδ-T cells. We hypothesized that blocking production will limit progression reducing recruitment of inflammatory Herein, we tested the potential 2 novel inverse agonists (2,3 derivatives 4,5,6,7-tetrahydro-benzothiophene) mouse model CCl4-induced injury. C57BL/6 mice received weekly injections...
Artemis (DCLRE1C) deficiency causes radiosensitive severe combined immunodeficiency (SCID), although hypomorphic cases can manifest later-onset immunodeficiency, autoimmunity, or lymphoproliferation. We report a 45-year-old man with humoral opportunistic infections, and recurrent EBV-positive diffuse large B-cell lymphoma (DLBCL). Genetic analysis was performed to identify mutations in the DCLRE1C gene. Functional studies, including γH2AX assays assess DNA damage repair measurement of Type I...
4046 Background: Perioperative chemotherapy improves cure rate in locally advanced gastroesophageal adenocarcinoma (GEA), and immune checkpoint inhibitors are active at the metastatic stage. This trial tests hypothesis that addition of avelumab to perioperative will increase major pathologic response (MPR) comparison with historical controls. Methods: Phase II study + (docetaxel, cisplatin 5-FU or mDCF) given every 2 weeks for 4 cycles before after surgery. Main inclusion criteria: GEA, cT3...
The transition towards digital pathology and an extensive selection of video conferencing platforms have helped provide continuity to education even during the COVID-19 pandemic. Innovative approaches for education, will likely persist beyond pandemic, as they powerful didactic potential. While there is a wide software use educational tools, environment access all resources with ease clearly lacking. In this technical note, we highlight our customized applications built using low-code...
It has recently been reported that mismatch repair (MMR) status and microsatellite instability (MSI) in gastroesophageal carcinomas predict surgical, chemotherapeutic immunotherapeutic outcomes; however, there is extensive variability the incidence clinical implications of MMR/MSI gastroesophaegal adenocarcinomas. We characterized a Canadian surgical patient cohort with respect to MMR status, clinicopathologic correlates anatomic tumour location.We investigated BRAF V600E adenocarcinomas...
No biomarkers are recommended for patients undergoing radiation-based therapy (RT) muscle-invasive bladder cancer (MIBC).We aim to evaluate the predictive role of programmed death-ligand 1 (PD-L1) expression on oncological outcomes treated with RT MIBC.A single-center retrospective analysis tumor specimens collected through transurethral resection (TURBT) from 104 MIBC patients, implemented in a tissue microarray and stained SP263 PD-L1 clone (Ventana Medical Systems, Tucson, AZ, USA), was...
ABSTRACT Background Rapid and accurate identification of mismatch repair (MMR) deficiency Lynch syndrome is critical in the prognostication clinical management patients with colorectal carcinoma. Case Description We describe here a young woman who developed locally aggressive rectal adenocarcinoma intact MMR protein expression by immunohistochemistry absence histologic evidence deficiency‐associated increased tumoral immune response. Germline DNA‐targeted sequencing identified MSH2 variant...
4055 Background: Perioperative chemotherapy improves cure rate in locally advanced gastro-esophageal adenocarcinoma (GEA). Immune checkpoint inhibitors have activity GEA. This trial is testing the hypothesis that addition of avelumab, an anti-PD-L1 antibody, to perioperative mDCF chemotherapy, will increase pathologic complete response (pCR) rate, a potential surrogate for overall survival, comparison with historical pCR 7%. Methods: Single-arm phase II study (NCT03288350) avelumab +...
We report a case of primary malignant solitary fibrous tumor (SFT) the urinary bladder in previously healthy 35-year-old male. The unusual presentation, focal GATA3 expression biopsy and excessive rarity entity at involved location all contributed to challenging diagnosis, which was finalized with resection specimen. Review literature highlighted this but revealed relatively positive outcome, no previous reports disease recurrence. therefore describe first SFT associated pulmonary metastases.
<title>Abstract</title> Perioperative chemo-immunotherapy represents a promising treatment modality for locally advanced gastroesophageal adenocarcinoma (GEA). However, the potential of these novel treatments has yet to be realized and efforts identify patients who would benefit targeted therapies have been unsuccessful. Herein we present clinical results phase 2 trial combining neoadjuvant docetaxel, cisplatin, 5FU PD-L1 inhibitor avelumab with GEA describe tumor inflammatory...
You have accessJournal of UrologyBladder Cancer: Invasive II (MP41)1 Sep 2021MP41-14 IMPACT OF PD-L1 EXPRESSION IN THE TUMOR MICROENVIRONMENT ON ONCOLOGICAL OUTCOMES FOR PATIENTS TREATED WITH TRIMODALITY THERAPY MUSCLE INVASIVE BLADDER CANCER: A POTENTIAL BIOMARKER PATIENT SELECTION? Gautier Marcq, Gertruda Evaristo, Ronald Kool, Surashri Shinde-Jadhav, Rodrigo Skowronski, Jose Joao Mansure, Luis Souhami, Fabio Cury, Fadi Brimo, and Wassim Kassouf MarcqGautier Marcq More articles by this...